Home / Neuromodulation & Neuro-Implants / Neuromodulation PMCF & Registry CRO

Post-market clinical evidence · Active implantable neurostimulation

Neuromodulation PMCF & Registry CRO for SCS, DBS & VNS

Design and run long-term PMCF, registry and real-world evidence programs for spinal cord, deep brain, vagus nerve and other active neurostimulation devices, with clinical operations, electronic data capture, monitoring, biostatistics and regulatory reporting integrated through one Eclevar program-governance model.

From long-term safety and performance questions or residual clinical evidence gaps, through extended implant follow-up, to the PMCF evaluation report and the clinical evaluation it supports.

SCS
DBS
VNS
Active implantable devices
PMCF
Registry
EU MDR

Discuss Your Neuro PMCF Program Request a PMCF Evidence Review

Class III implantable neurostimulation evidence strategy delivered for a confidential manufacturer submission
Regulatory and ethics start-up led and coordinated by Eclevar, using in-house delivery or qualified local support according to the country and the applicable submission pathway
Data management, biometrics and medical writing coordinated centrally across the program

Where this starts

Talk to Eclevar when one of these is true.

Your clinical evaluation leaves an unresolved long-term evidence gap.
You need SCS, DBS or VNS long-term follow-up in Europe.
Your existing registry does not capture programming, revision or explant data adequately.
Your PMCF plan calls for prospective clinical evidence rather than further literature review.

Attrition is making an existing long-term dataset difficult to interpret.
You need to decide between a prospective PMCF study, a registry or a combined model.
You need one data architecture across several implant generations or indications.
The output has to feed both the PMCF evaluation report and the clinical evaluation.

The therapeutic problem

Neuromodulation PMCF has to follow the implant, the patient and the therapy over time.

Most post-market plans are written around a visit schedule. For an active implantable neurostimulator, clinically important events that may materially affect the benefit-risk evaluation do not necessarily align with scheduled study visits. They arrive when a lead migrates, when a battery reaches end of service, when a patient stops using the therapy, or when a programming change quietly redefines what the device was actually delivering.

Whether the benefit is sustained

For long-term implantable-device evidence, an initial treatment response is often only part of the question. The clinical evaluation may also need to establish whether benefit is sustained over time. Depending on the device and the indication, that can be carried by responder persistence, functional outcomes, quality of life, symptom trajectory or therapy continuation. Which outcomes carry the long-term evidence argument should be defined prospectively in the protocol, registry plan or statistical strategy.

The implant lifecycle, not the visit calendar

Revision, replacement, lead migration, reoperation, explant, device deficiency and therapy discontinuation sit on different clinical timelines, and reporting conventions differ between centers. A dataset that captures the visit but not the reoperation cannot reliably characterize revision burden, an important component of long-term implantable-device evidence.

Programming as a variable, not a footnote

A neurostimulator is not a fixed intervention. Device-specific therapy parameters, which may include amplitude, frequency, pulse width, contact configuration or other system-specific programming variables, vary between patients and over time. Where that history is not held in structured, queryable form, the analysis may be unable to reconstruct treatment exposure consistently when clinically relevant programming history is not captured in structured form.

Residual risk, stated before the budget

PMCF creates value when its objectives are explicit. Those objectives may include confirming long-term safety or performance, evaluating the continued acceptability of identified risks, identifying emerging risks, closing a residual clinical-evidence gap or addressing a clinical question that the existing evidence does not adequately answer. The evidence model should therefore be designed from the PMCF objective backward rather than beginning with a generic follow-up template.

The decision

Does your evidence gap need a PMCF study, a registry, or both?

The general version of this decision, across all device types, is set out on the PMCF study and post-market evidence page. What follows is what changes when the device is an active implantable neurostimulator.

A PMCF clinical investigation may fit where

a specific hypothesis or clinical claim needs a controlled, protocol-defined evaluation
the design requires a defined intervention, comparator or assessment framework
the population or treatment strategy is deliberately constrained
assessment timing and protocol control are important to the interpretation

A registry may fit where

the objective is to characterize long-term safety, performance, therapy persistence, revision, replacement, explant or clinical outcomes across a defined real-world population
clinically relevant events need observation at scale
longitudinal observation over extended periods is important
variation in real-world practice is itself relevant to the evidence question

Figure 1. Which fit signals point to a prospective PMCF study and which point to a registry. The signals describe the evidence question, not a preferred model.

Some neurostimulation evidence strategies may require both, with the registry extending or complementing a prospective investigation rather than simply duplicating it.

Whether the registry contributes meaningfully to PMCF depends on its design, its methodology and its relationship to the actual evidence question.

Review the Right Evidence Model

By system family

The post-market evidence priorities differ by neurostimulation modality.

Spinal cord and dorsal root ganglion stimulation

Responder durability read over years rather than at the end of the trial period. The pain and function instruments that carry the argument, and the timepoints at which they are read. Lead-related events including migration and fracture. Revision and explant with the reason recorded, including explant for loss of efficacy. Therapy discontinuation. Analgesic use as a confounder that moves over the follow-up period. Patient-reported outcome completeness across a long horizon.

Deep brain stimulation

Indication-specific clinical outcomes and the longitudinal rating scales that carry them, with medication state and assessment timing recorded rather than assumed. Programming changes and who made them. Imaging review where lead position is part of the question. Device-related events, revision and replacement. Battery, recharge or replacement considerations where relevant to the system and the evidence question.

Vagus nerve stimulation

Event-frequency outcomes where the indication supports them. Titration history treated as a study variable rather than as background clinical activity. Therapy persistence and discontinuation. Patient-reported outcomes and diary completeness over long periods. Device events and revision.

Other active neurostimulation systems

Peripheral nerve stimulation, sacral neuromodulation, responsive and closed-loop systems, and newer implantable neurotechnology. For systems in which software, firmware or algorithm versions can change during the observation period, version traceability may form part of the post-market dataset: which version each patient was on, when it changed, and whether any follow-up data spans a version boundary.

Data architecture

The dataset should follow the device lifecycle, not only the visit schedule.

Baseline
Implant
Programming
Scheduled follow-up
Clinical response
Device event
Revision or replacement
Explant
Continued follow-up

Figure 2. The implant lifecycle a neurostimulation post-market dataset has to follow. Device event, revision and explant are branches rather than scheduled steps, which is why a visit-driven dataset misses them.

Long-term implant data is what allows durability, device performance, clinical benefit, safety, revision burden and therapy persistence to be argued separately rather than collapsed into one summary. Each is a different question, and each needs its own variables.

Domains a neurostimulation post-market dataset usually has to hold

Patient characteristics and indication
Device identification and UDI
Implant procedure
Lead and electrode information
Device configuration and programming history
Clinical outcomes

Patient-reported outcomes
Concomitant therapies
Device deficiencies
Adverse events and adverse device effects where applicable
Revision, replacement and explant with reason
Therapy status and follow-up status

What keeps the dataset usable years later

Edit checks written against the endpoint rather than against a template. Query management and a complete audit trail. Coding applied consistently across sites and across years. Traceability from the record back to source. Data quality reviewed while the program runs, not at the end of it.

Electronic data capture and the longitudinal structures this depends on are described on the clinical data management and EDC page.

Capability

One program, from the PMCF question to the regulatory document it feeds.

PMCF strategy and evidence-gap review

What the clinical evaluation, the PMS output and the risk management file leave unresolved, and which evidence model answers it.

Registry design

Population, eligibility, data model, contact schedule, long-term follow-up structure, site model and governance, including whether an existing specialty or national registry already holds the population.

Plans and protocols

Clinical investigation plan, PMCF plan, registry protocol, statistical analysis plan, monitoring plan and data management plan, as the model requires.

Implanting-center feasibility and activation

Implant volume in the population your protocol defines, investigator experience, programming capacity, whether revision and explant are performed on site or referred, and competing studies already open.

Clinical operations and monitoring

Site activation and management, central and remote monitoring, targeted on-site review where justified, deviation follow-up and device-event follow-up.

EDC and clinical data management

Structured capture of device identification, implant details, programming history, outcomes, revision and explant, device deficiencies and follow-up status, reconciled against device or programmer exports where those exist.

Biostatistics and real-world evidence analysis

Longitudinal outcomes, responder persistence, time-to-event analysis where the data support it, missing-data handling and pre-specified subgroups.

PMCF evaluation report and CER integration

The output written into the PMCF evaluation report and from there into the clinical evaluation, by the people who were in the room when the endpoints were defined.

Data quality and monitoring

A large registry is not useful if the variables that carry the argument are incomplete.

The variables that materially affect whether a long-term neurostimulation dataset can answer its intended clinical question are a small subset of the variables collected. Endpoint completeness, follow-up completeness, device-event capture and revision or explant capture are the ones worth monitoring continuously. Missingness, query aging, site performance and internal consistency are read as trends rather than as end-of-study findings.

Critical variables
Completeness thresholds
Central review
Queries
Site follow-up
Corrective action where needed
Trend review
Analysis-ready dataset

Figure 3. The data-quality loop. It runs continuously against the four critical variables named above, and returns to them rather than ending at the dataset.

What monitoring concentrates on in a long-term implant program

Consent and eligibility
Device identification
Implant and programming records
Endpoint completion inside the visit window
Device deficiencies
Revision and explant capture
Loss to follow-up
Patient-reported outcome completeness
Consistency between the study record and source

The default is central and remote review, risk-based, with targeted on-site review where a variable or a site justifies it. Monitoring scope, intensity and country model are described on the clinical trial monitoring services page, and the on-site and remote delivery model in more detail on the on-site and remote monitoring page.

Biostatistics

Long-term neurostimulation evidence needs more than a baseline-to-endpoint comparison.

Repeated measures and longitudinal outcomes rather than a single change score. Persistence of responder status, where the responder definition has been justified for the indication. Time-to-event analysis for revision and explant where the follow-up and the event count support it. Attrition and missing data planned for before enrollment, subgroups stated in advance, and heterogeneity of real-world practice treated as a feature of the dataset rather than as noise.

The method follows the question. Analytical approach, sample-size assumptions and the statistical analysis plan are set out on the medical device biostatistics page.

Regulatory evidence flow

The evidence has to arrive somewhere, and that place is a document.

Residual risk or CER gap
PMCF question
Protocol or registry design
Site activation
Patient follow-up
Monitoring and data quality
Statistical analysis
PMCF evaluation report
CER and PMS update

Figure 4. From the residual risk that opens the question to the two documents that close it, the clinical evaluation report and the post-market surveillance cycle.

Post-market clinical data does not stay inside the clinical function. Device deficiencies and revision patterns are read alongside complaint handling and vigilance, and a signal that appears in a registry may need to be reconciled with the risk management file and, where procedures require it, with corrective and preventive action.

Evidence experience

Relevant Class III and long-term evidence experience.

Confidential Class III implantable neurostimulation program Neuromodulation · Active implantable device · Europe Advisory contribution

Evidence strategy and post-market evidence architecture behind a Class III neurostimulation submission

Eclevar contributed to the evidence strategy, mapped clinical-evidence questions relevant to Class III technical-documentation review and built the post-market evidence architecture behind a confidential Class III implantable neurostimulation submission.

What the existing dataset supported, where it stopped, and what had to be generated
The long-term benefit argument drafted before the question was asked
The variables and timepoints needed to support a responder definition
Structured capture of stimulation settings, program changes and device configuration
A post-market follow-up architecture designed to feed the clinical evaluation it supports

Eclevar's role was advisory. No regulatory outcome is claimed: conformity assessment decisions belong to the manufacturer and the Notified Body.

Perouse Medical, Vygon Group

Therapeutic area: Class III implantable vascular devices

Six registered observational post-market studies across three device families, built on one harmonized evidence model rather than six unrelated studies. What transfers to a neurostimulation portfolio is the architecture: consistent definitions, traceable records and one governance model applied across a device family. Eclevar structured the program architecture and supports delivery.

RegenLab

Therapeutic area: advanced wound care

160 participants across 14 clinical sites in a prospective multicountry European PMCF program, with two parallel indication cohorts held separable in one data model. What transfers is the delivery model: multiple national regulatory and ethics routes led and coordinated by Eclevar, and one centrally coordinated Eclevar program model across clinical operations, data management, biostatistics and reporting.

How an engagement begins

Three ways to engage Eclevar.

Option 1. Neuromodulation PMCF evidence review

Best for: sponsors who already have a PMCF plan, a clinical evaluation or an unresolved evidence question.

What you bring: existing clinical evaluation · PMCF plan · PMS output · risk-management questions · current clinical dataset.

What you leave with: an evidence-gap assessment, a study or registry recommendation, endpoint and data requirements, a proposed follow-up model and an initial execution roadmap.

Request a PMCF Evidence Review

Option 2. Registry or PMCF study design and setup

Best for: sponsors who know they need additional long-term evidence but have not yet built the operating model.

Typical scope: protocol or PMCF plan · registry architecture · endpoint strategy · statistical analysis plan · EDC and CRF architecture · feasibility · site model · monitoring model · reporting pathway.

Design Your Neuro PMCF Program

Option 3. Full-service neuromodulation PMCF and registry CRO

Best for: sponsors requiring execution from evidence strategy through long-term follow-up and reporting.

Typical scope: European feasibility · start-up · site management · monitoring · data management and EDC · biostatistics · reporting · PMCF evaluation · CER integration.

Scope Full-Service Delivery

Governance

The team behind your neuro PMCF evidence program.

Eclevar leads clinical evidence strategy, European study delivery, biometrics and regulatory integration. Indication-specific medical oversight is defined according to program needs and may involve sponsor investigators and appropriately qualified independent neurology, neurosurgery or other relevant specialists.

Dr Mark Da Costa

Chief Operating Officer

Clinical evidence strategy informed by first-hand Notified Body review experience, applied to how a Class III post-market evidence argument is structured and defended. Focus: testing whether the evidence model is structured to address the clinical and regulatory questions likely to arise during review.

Sébastien Meier Piantanida

Chief Data Officer · Head of Biometry

Electronic data capture design for stimulation settings and device configuration, database governance, statistics and the analysis-ready dataset. Focus: whether the planned dataset can support the intended analyses, and how missing data, longitudinal structure and device variables may affect interpretability.

Pierre-Marie Boutanquoi

Head of Medical Writing

PMCF evaluation reports, clinical evaluation reports and Notified Body response handling. Focus: whether the planned outputs are structured so they can contribute appropriately to PMCF evaluation and clinical evaluation reporting.

Modality-specific support

Dr Nikhil Khadabadi

CMO · Orthopaedics & Spine · NHS Surgeon

SCS-specific implantable-device methodology, spinal pathway design, and the revision and explant workflows a spinal cord stimulation program has to specify. Scope: spinal cord stimulation support only. Not a medical lead for deep brain stimulation, vagus nerve stimulation or neuromodulation generally.

Former positions are stated for biographical context only. Eclevar MedTech is an independent contract research organization. It is not affiliated with, accredited by or endorsed by any Notified Body, and Notified Body names referred to on this site are the trade marks of their respective owners. Notified Bodies issue certificates; individual reviewers assess technical documentation and clinical evidence.

Why sponsors bring this program to Eclevar

A medical device CRO only. No pharmaceutical service line competing for the same people.
Class III implantable evidence methodology, applied to the post-market question rather than borrowed from the pre-market one.
Registry design, clinical operations, data management, biostatistics and medical writing inside one team, so the dataset is specified by the people who will have to report from it.
European multicountry delivery through a combination of central program governance, regional clinical operations and qualified local coverage where appropriate.

Questions

Questions neuromodulation sponsors ask about post-market evidence.

Can a registry be used for neuromodulation PMCF?

It can, where the registry is designed against the specific post-market question and the methodology and regulatory rationale are set out for the device and indication concerned. It is not automatic. A registry may be well suited to questions such as durability, device survival, revision burden, therapy persistence and other long-term outcomes across a defined population. Where the evidence question requires scheduled assessments, trained clinical ratings or imaging that routine-care data do not capture reliably, a routine registry may not be sufficient unless it is specifically designed to collect those assessments prospectively.

How long should a neurostimulation registry follow patients?

The follow-up horizon should be justified against the clinical question, device characteristics, intended use, expected timing of relevant safety and performance events, residual risks and the evidence gap the program is intended to address. For implanted systems, expected device service life may be an important input, particularly when battery longevity, revision, replacement or late device events form part of the evidence question. Retention assumptions and the statistical consequences of attrition should be addressed prospectively.

What should an SCS PMCF program collect?

Depending on the evidence gap: responder status at defined timepoints with the definition justified for the indication, pain and function instruments, therapy continuation and discontinuation, analgesic use as a confounder, lead migration and fracture, revision and explant with the reason recorded, and device deficiencies. Programming history should be structured rather than free text.

What should a DBS PMCF program capture?

Depending on the indication, device and clinical claims: longitudinal clinical rating scales with medication state and assessment timing recorded, programming changes, device-related events, revision and replacement, and battery, recharge or replacement considerations where relevant to the system. Where lead position is part of the question, an imaging review pathway has to be agreed before enrollment rather than reconstructed later.

How should revisions and explants be recorded in a neurostimulation registry?

Against an event taxonomy defined before the first patient is enrolled, so terminology remains consistent across the clinical database, complaint-handling, vigilance and quality-system workflows. Each event needs its date, its reason and its relationship to the device where applicable.

How do you reduce loss to follow-up in long-term implant registries?

By designing for it: realistic retention assumptions, a contact model that does not depend on one coordinator remaining in post, follow-up windows wide enough that a late visit stays analyzable, and completeness monitored as a live metric. Attrition cannot be eliminated over years, so it is measured and accounted for in the analysis.

Can Eclevar support a multicountry neuromodulation registry in Europe?

Yes. Eclevar supports multicountry European neuromodulation programs through central program governance, regional clinical operations and qualified local coverage where appropriate. Data management, biometrics and medical writing are coordinated centrally across the program, and Eclevar leads and coordinates regulatory and ethics start-up according to the country, the authority and the applicable submission pathway. Country-specific coverage is discussed during feasibility.

Can registry data feed the PMCF evaluation report and the clinical evaluation?

Yes, where the registry has been designed against the relevant PMCF and clinical-evaluation questions. The required variables, definitions, follow-up structure, data-quality controls and analytical plan should be established prospectively, so that the resulting dataset can support the PMCF evaluation and the broader clinical evidence strategy where appropriate.

How does post-market clinical data connect to ISO 13485 and CAPA?

Device deficiencies, revision patterns and explant reasons observed in a post-market program are read alongside complaint handling, vigilance and the risk management file. Where the manufacturer's quality system requires it, a signal identified in the data may trigger corrective and preventive action. Designing the event taxonomy so it maps onto the quality system's terminology avoids the same event existing twice, described two different ways.

Next step

Planning a PMCF or registry program for a neurostimulation device?

Bring the device, intended indication, existing clinical evidence, residual-risk questions and current PMCF plan. We will use them to frame the evidence gap, the study or registry model, European site strategy, data architecture and reporting pathway before the program scope and budget are finalized.

Request a Neuromodulation PMCF Review Discuss a Neuro Registry Program